Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9121973 | 0.95 | ACACB (0.60) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| Biphenyl SCHEMBL9839827 | 0.94 | ACACB (0.59) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL24533732 | 0.91 | RXRA (0.58) | ALOX5RXRARXRB | |
| SCHEMBL17602110 | 0.89 | ALOX5 (0.53) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL17602106 | 0.86 | MAPT (0.71) | MAPTMAOBRAB9AMEN1KMT2A | |
| SCHEMBL10758358 | 0.85 | MEN1 (0.49) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL9127543 | 0.85 | ALOX5 (0.63) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL3239740 | 0.85 | LMNA (0.66) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL11606393 | 0.85 | LMNA (0.66) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL683554 | 0.85 | RXRA (0.66) | LMNACYP1A2PTGS1SLC6A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107880085-B | Use of [ Rnim][OSO2OR]Method for synthesizing salidroside by Lewis acid ionic liquid system | 枣庄学院 | 2021-04-09 | — | — | CN | claimed |
| CN-110818560-A | Preparation method of 4-benzyloxy phenyl ethyl n-decanoate | 怀化金鑫新材料有限公司 | 2020-02-21 | — | — | CN | claimed |
| CN-102898289-B | Method for synthesizing 2-(4-benzylmethoxyphenyl)ethanol medical intermediate | Jiangsu defeng pharmaceutical co ltd | 2014-09-03 | — | — | CN | claimed |
| CN-102898289-A | Method for synthesizing 2-(4-benzylmethoxyphenyl)ethanol medical intermediate | Jiangsu defeng pharmaceutical co ltd | 2013-01-30 | — | — | CN | claimed |
| US-7019172-B2 | Process for preparation of S-(-)-betaxolol and salts thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-03-28 | — | — | US | claimed |
| US-20060004109-A1 | Cyclopropanating 1-(2-allyloxyethyl)-4-benzyloxybenzene by the Simmon-Smith reaction with Furukawa modification to obtain the enantiomer 1-benzyloxy-4-(2-cyclopropyl methoxyethyl)benzene of high purity; avoiding the use of highly lacrymatric and unstable cyclopropylmethyl halide | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-01-05 | — | — | US | claimed |
| CN-114213248-A | Preparation method of 4-benzyloxy phenyl ethyl n-decanoate | 郑州睿嘉纳米新材料科技有限公司 | 2022-03-22 | — | — | CN | disclosed |
| WO-2020141439-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2020-07-09 | — | — | WO | disclosed |
| WO-2020141439-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2020-07-09 | — | — | WO | disclosed |
| US-20200206233-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2020-07-02 | — | — | US | disclosed |
| US-20200206233-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2020-07-02 | — | — | US | disclosed |
| CN-110818560-A | Preparation method of 4-benzyloxy phenyl ethyl n-decanoate | 怀化金鑫新材料有限公司 | 2020-02-21 | — | — | CN | disclosed |
| CN-110818560-A | Preparation method of 4-benzyloxy phenyl ethyl n-decanoate | 怀化金鑫新材料有限公司 | 2020-02-21 | — | — | CN | disclosed |
| US-7935713-B2 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2011-05-03 | — | — | US | disclosed |
| US-7902175-B2 | Aminopropanol derivatives | NOVARTIS AG (CH) | 2011-03-08 | — | — | US | disclosed |
| CN-101528669-A | Deuterated aminoglycidyl compounds | AUSPEX PHARMACEUTICALS INC (US) | 2009-09-09 | — | — | CN | disclosed |
| US-20090156556-A1 | AMINOPROPANOL DERIVATIVES | ALBERT RAINER | 2009-06-18 | — | — | US | disclosed |
| US-20090105310-A1 | Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds and Methods of Use | MERCK SHARP & DOHME LLC | 2009-04-23 | — | — | US | disclosed |
| US-7019172-B2 | Process for preparation of S-(-)-betaxolol and salts thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-03-28 | — | — | US | disclosed |
| US-20060004109-A1 | Cyclopropanating 1-(2-allyloxyethyl)-4-benzyloxybenzene by the Simmon-Smith reaction with Furukawa modification to obtain the enantiomer 1-benzyloxy-4-(2-cyclopropyl methoxyethyl)benzene of high purity; avoiding the use of highly lacrymatric and unstable cyclopropylmethyl halide | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206233-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | IDH1, IDH2, IDH3A | LMNA 3920/4885CYP1A2 408/4885PTGS1 707/4885 |
| US-20090105310-A1 | Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds and Methods of Use | GCGR, GLP1R, GPR119 | LMNA 2268/4885CYP1A2 1996/4885PTGS1 1014/4885 |
| US-20090156556-A1 | AMINOPROPANOL DERIVATIVES | ADRB1, ADRA1D, ADRA1A | LMNA 2021/4885CYP1A2 17/4885PTGS1 625/4885 |
| US-20060004109-A1 | Cyclopropanating 1-(2-allyloxyethyl)-4-benzyloxybenzene by the Simmon-Smith reaction with Furukawa modification to obtain the enantiomer 1-benzyloxy-4-(2-cyclopropyl methoxyethyl)benzene of high purity; avoiding the use of highly lacrymatric and unstable cyclopropylmethyl halide | SMAD2, SPHK1, TGFBR1 | LMNA 2697/4885CYP1A2 450/4885PTGS1 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.